Elevidys timeline raises questions about Sarepta’s and FDA’s decisions and disclosures

There was more disturbing news for Duchenne muscular dystrophy patients Friday as FDA announced an investigation of the death of an 8-year-old boy who had received Sarepta’s Elevidys gene therapy.

The news, like the leaks and statements from Sarepta Therapeutics Inc. (NASDAQ:SRPT) and FDA in recent days, raised questions about the responsibilities of companies and regulators to disclose information about fatal events that are or could be related to a treatment, and highlighted the contentious circumstances surrounding the testing, approval and use of Elevidys...